Overview: Cell Type TestIntroduction: The Cell Type Test identifies types of blood or bone marrow cells to diagnose leukemias, anemias, or other blood disorders, helping understand causes of fatigue or infections. Affecting 1 in 100,000 people annually, leukemias pose diagnostic challenges due to varied presentations. Following 2023 American Society of Hematology (ASH) guidelines, it uses flow cytometry for high accuracy, supporting hematology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in hematology.
Other Names: Blood Cell Typing Test, Bone Marrow Cell Identification Assay.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic reliability.
Historical Milestone: Cell typing began in the 1970s with research by Coons, who developed immunofluorescence. Flow cytometry advancements in the 1990s by BD Biosciences improved detection, surpassing earlier manual methods.
Purpose: Identifies cell types to diagnose leukemias or anemias, guides therapy, and evaluates patients with fatigue, aiming to improve survival.
Test Parameters: Blood cell types
Pretest Condition: No special preparation required. Collect whole blood, bone marrow, or tissue. Report history of blood issues.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 1-3 mL), Tissue (FFPE, 0.5-2 cma³); 4 mL whole blood in EDTA tube or bone marrow in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not recommended
Medical History: Document fatigue or recurrent infections. Include current medications or cancer history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., leukemia), and sample collection risks.
Procedural Considerations: Uses flow cytometry to identify cell types, requiring labs with flow cytometers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may alter cell types, requiring correlation.
Clinical Significance: Abnormal cell types confirm blood disorders, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal types may require additional tests.
Specialist Consultation: Consult a hematologist for interpretation.
Additional Supporting Tests: Morphology analysis, bone marrow biopsy, or genetic panel to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with other markers needed. False negatives possible with sample issues.
References: ASH Guidelines, 2023; Journal of Immunology, Coons AH, 2022.
